Brings assets under management to $1.2 billion
CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ --
Clarus Ventures, LLC ("Clarus Ventures"), a leading life sciences venture
capital firm, announced today the single close of Clarus Lifesciences II,
L.P. ("Clarus II"), a $660 million fund in Limited Partner commitments.
This is the second investment fund formed and managed by Clarus Ventures,
since the firm was established in 2005.
Clarus II will invest $20-60 million in biotechnology, specialty
pharmaceutical and medical technology companies that are developing
innovative products for the treatment of human diseases. The firm's first
fund has committed 90 percent of its proceeds to date.
"We have effectively completed the deployment of our first fund and
built a diversified portfolio of exciting companies," said Robert Liptak, a
Clarus Ventures Managing Director. "These include companies with strong
growth in revenue and profitability such as Globus Medical; products near
commercialization such as Sientra, Pelikan, Oxford and Zogenix; and those
with breakthrough products and technologies such as Aerovance, Centaurus,
CoMentis, ESBATech, Pearl, ProActa, SarCode, Taligen, and Variation. We
plan to follow a similar investment strategy for Clarus II. With the
diversity and depth of our team we believe we can leverage our experience
to identify and help grow leading companies in the life sciences field."
The Limited Partner base for Clarus II was effectively the same as in
Clarus I. A small, select group of new high-quality investors who knew the
firm well also participated.
The Clarus Ventures team is led by Nicholas Galakatos, Dennis Henner,
Jeffrey Leiden, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt
Wheeler, an established group of investment professionals with deep and
complementary backgrounds within the life sciences industry. The team
uniquely balances broad investing expertise with leadership experience in
major biotechnology and pharmaceutical companies.
About Clarus Ventures
Founded by a group of accomplished investment professionals with
extensive and complementary industry backgrounds, Clarus Ventures is a life
sciences venture capital firm with a team that has a long history of
success in creating value. Internal operating experience combined with
longstanding relationships with key opinion leaders and industry thought
leaders and decision makers allow this team to identify unique investment
opportunities and shepherd them to maturity. Clarus Ventures augments its
core expertise of investing in biopharmaceuticals and medical technology
with deep and diverse expertise in research and development,
commercialization, business development and operations management at the
global level. The firm has $1.2 billion under management and has offices in
Cambridge, Mass., and South San Francisco, CA.
For additional information on Clarus Ventures, please visit
http://www.clarusventures.com.
CONTACTS:
Nicholas Galakatos, Ph.D., Clarus Ventures, Tel.: 617-949-2223
Robert Liptak, Clarus Ventures, Tel.: 617-694-2222
Tony Russo, Russo Partners, Tel.: 212-845-4251
SOURCE Clarus Ventures, LLC
 back to top
Related links:
http://www.clarusventures.com
CONTACT:
Nicholas Galakatos, Ph.D., +1-617-949-2223,
or Robert Liptak, +1-617-694-2222, both of Clarus Ventures; or
Tony Russo of Russo Partners, +1-212-845-4251
|
